BI-1910 clinical trials

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

This study is testing a new drug, BI 1910, for people with advanced cancers. It will check how safe the drug is, what side effects it causes, and how much of it the body can handle, both on its own and when given with another cancer drug.